Literature DB >> 2644991

Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of the bleeding disorder by cell differentiation.

P W Wijermans1, V I Rebel, G J Ossenkoppele, P C Huijgens, M M Langenhuijsen.   

Abstract

In the human promyelocytic cell line HL60, we observed both a strong procoagulant activity (PCA) on the cell membrane and proteolytic activity in the lysate of these cells. Because these cell-line cells are susceptible to differentiation to either a more mature granulocytic or monocytic form, we were able to study the hypothesis that the combination of PCA and proteolytic activity is confined to the promyelocyte. This may explain the severe coagulopathy seen in patients with acute promyelocytic leukemia. Cell differentiation in a myeloid direction induced by retinoic acid or DMSO led to a diminished PCA, while not affecting the fibrinolytic activity. On the other hand, monocytic differentiation obtained by culturing the cells in the presence of 1; 25 dihydroxy vitamin D3 led to the complete disappearance of the proteolytic activity of the cell lysate, although the procoagulant activity was still present. Furthermore, we found that the elastase activity almost disappeared after monocytic differentiation. We also studied the PCA, proteolytic activity, and elastase activity of blast cells of patients with acute myeloid leukemia. Only in patients with acute promyelocytic leukemia did we observe both a strong PCA and fibrinolytic activity. This supports our hypothesis that the combination of these activities is unique to the promyelocyte and may explain the observed bleeding complications in patients with acute promyelocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644991

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.

Authors:  I Pabinger; P Bettelheim; R Dudczak; W Hinterberger; P A Kyrle; H Niessner; I Schwarzinger; W Speiser; K Lechner
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

2.  Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays.

Authors:  H T Hassan; A Veit; H R Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Actinomycin D upregulates lipopolysaccharide induction of macrophage procoagulant expression and tumour necrosis factor-alpha production.

Authors:  H R Wheeler; E J Rockett; I Clark; C L Geczy
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 4.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 5.  Hemostatic alterations in cancer patients.

Authors:  F R Rickles; M Levine; R L Edwards
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

6.  New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia.

Authors:  H T Hassan; L E Zyada; M H Ragab; J K Rees
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.